Vanguard Portfolio Management
NERV icon

Vanguard Portfolio Management’s Minerva Neurosciences NERV Stock Holding History

Vanguard Portfolio Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
+234,754
New +$1.27M ﹤0.01% 2881

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management's NERV Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Minerva Neurosciences (NERV) in Q2 2026: 234,754 shares worth $1.3M. The stake represents ﹤0.01% of the portfolio and ranks #2881 among its holdings.

60 funds tracked by Wall St. Rank hold NERV as of Q2 2026.

  • Vanguard Portfolio Management held 234,754 shares of Minerva Neurosciences worth $1.3M as of Q2 2026.
  • Minerva Neurosciences was a new Vanguard Portfolio Management position in Q2 2026.
  • Minerva Neurosciences made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2881 holding.
  • 60 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.